157 related articles for article (PubMed ID: 2545953)
1. [Clinical evaluation of PIVKA-II in patients with hepatocellular carcinoma. Detection of PIVKA-II by EIA using anti-PIVKA-II monoclonal antibody].
Ohtani M; Ido K; Kawamoto C; Kimura K
Rinsho Byori; 1989 Apr; 37(4):405-9. PubMed ID: 2545953
[No Abstract] [Full Text] [Related]
2. [Fundamental studies, reference values, and clinical evaluation of abnormal prothrombin PIVKA-II assay using monoclonal antibody (E-1023)].
Sakurabayashi I; Kawai T; Omizo R; Hattori N; Ishii M
Rinsho Byori; 1988 Dec; 36(12):1407-12. PubMed ID: 2854864
[No Abstract] [Full Text] [Related]
3. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H
Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525
[TBL] [Abstract][Full Text] [Related]
4. [A staining method of PIVKA-II by an indirect immunoenzyme technic].
Tanimoto K; Onji M; Nadano S; Kumon I; Michitaka K; Horiike N; Ohta Y
Rinsho Byori; 1989 Oct; 37(10):1139-42. PubMed ID: 2481050
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma].
Tada H; Kagawa K; Hikita H; Takeuchi T; Ohta Y; Fukui S; Shintani H; Deguchi T; Okanoue T; Takino T
Gan No Rinsho; 1989 Apr; 35(5):564-70. PubMed ID: 2469809
[TBL] [Abstract][Full Text] [Related]
6. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
Fujiyama S; Morishita T; Shibata J; Sato T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
[TBL] [Abstract][Full Text] [Related]
7. [Clinical signification and evaluation of PIVKA-II in hepatocellular carcinoma].
Matsushima A; Enomoto M; Yokoo Y; Arai M; Kobayashi T; Okuno F; Hirano Y; Sujita K; Eto S; Takagi T
Rinsho Byori; 1989 Jun; 37(6):683-6. PubMed ID: 2477568
[No Abstract] [Full Text] [Related]
8. [Clinical usefulness of serum PIVKA-II levels determined by ECLIA system as a tumor maker for hepatocellular carcinoma].
Sakizono K; Oita T; Shibata Y; Tamura A; Kasakura S
Rinsho Byori; 1998 Sep; 46(9):936-41. PubMed ID: 9800480
[TBL] [Abstract][Full Text] [Related]
9. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
[TBL] [Abstract][Full Text] [Related]
10. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].
Arima K; Kodama T; Suga M; Sakamoto H; Ohe Y; Yachi A
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968
[TBL] [Abstract][Full Text] [Related]
11. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
Lamerz R; Runge M; Stieber P; Meissner E
Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
[TBL] [Abstract][Full Text] [Related]
12. [Development of highly sensitive assay for detection of low serum level of PIVKA-II and its clinical usefulness].
Sakizono K; Oita T; Kuroda M; Kasakura S
Rinsho Byori; 1996 Sep; 44(9):871-6. PubMed ID: 8911073
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
[TBL] [Abstract][Full Text] [Related]
14. [Early diagnosis of hepatocellular carcinoma by serum AFP and PIVKA-II analysis].
Aoyagi Y; Yanagi M; Asakura H
Nihon Naika Gakkai Zasshi; 1995 Dec; 84(12):2003-7. PubMed ID: 8586921
[No Abstract] [Full Text] [Related]
15. Time courses of PIVKA-II and AFP levels after hepatic artery embolization and hepatic artery infusion against hepatocellular carcinoma: relation between the time course and tumor necrosis.
Kishi K; Sonomura T; Mitsuzane K; Nishida N; Kimura M; Satoh M; Yamada R; Kodama N; Kinoshita M; Tanaka H
Radiat Med; 1992; 10(5):189-95. PubMed ID: 1279748
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
17. [Tumor markers of hepatocellular carcinoma].
Kubo S; Matsukawa M
Gan To Kagaku Ryoho; 2004 Dec; 31(13):2203-6. PubMed ID: 15628773
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of des-gamma-carboxy prothrombin assay as a tumor marker].
Yamano M
Nihon Rinsho; 1990 Feb; 48 Suppl():999-1002. PubMed ID: 1693989
[No Abstract] [Full Text] [Related]
19. [Des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma].
Yamashiki M; Kosaka Y
Rinsho Byori; 1989 Feb; 37(2):118-21. PubMed ID: 2471846
[No Abstract] [Full Text] [Related]
20. [Tumor markers for hepatocellular carcinoma].
Tateishi R; Enooku K; Shiina S; Koike K
Nihon Rinsho; 2012 May; 70(5):821-7. PubMed ID: 22620007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
